Use of antioxidant for treating and/or preventing surface ocular disorders
OwnerMarie-Therese Droy-Lefaix, Christophe Baudouininventors
Life of this patent
Estimating the term…
Abstract
The invention relates to a pharmaceutical composition for the treatment of superficial eye disorders. According to the invention, an antioxidant, selected from the group comprising SODs, SOD mimetics and derivatives, racemic alpha-lipoic acid and its R+ or R− enantiomer, and mixtures of these compounds, is used for the manufacture of a drug for the treatment and/or prevention of superficial eye disorders. The invention is applied in human and veterinary medicine.
Claims22
Use of an antioxidant, selected from the group comprising superoxide dismutases (SODs), superoxide dismutase mimetics, superoxide dismutase derivatives, racemic alpha-lipoic acid, the R+ enantiomer of alpha-lipoic acid, the R− enantiomer of alpha-lipoic acid, and mixtures of these compounds, for the manufacture of a drug for the treatment and/or prevention of superficial eye disorders in humans or animals.
Use according to any one of the preceding claims, characterized in that the SOD and/or SOD derivative and/or mimetic is present in the drug at a concentration of between 1 μg/ml and 500 μg/ml, preferably of between 25 μg/ml and 50 μg/ml.
Use according to any one of the preceding claims, characterized in that the superficial eye disorders cause ocular dryness.
Use according to claim 21, characterized in that said preservative is benzalkonium chloride.
Use according to any one of the preceding claims, characterized in that the drug is in the form of an eyewash, a gel or an ointment that also contains pharmaceutically acceptable excipients.
Dependencies are inferred from the claim text.